Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1141 to 1150 of 2417

TitleReference numberPublishedLast updated
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasiaMIB306
Ivabradine for treating chronic heart failureTA267
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTA988
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Ixekizumab for treating axial spondyloarthritisTA718

Results per page

  1. 10
  2. 25
  3. 50
  4. All